Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eiken Chemical CoTSE:4549 -1.83%79 EV-to-EBITDA is 9.95 as of Aug. 28, 2026, which is 20% below its 10-year median of 12.39. GuruFocus rates TSE:4549 with a GF Score™ of 79/100 and a GF Value™ of 円2,494.71 (Fairly Valued). The stock has 4 warning signs investors should review. Among 523 Medical Devices & Instruments companies, Eiken Chemical Co ranks better than 65.39% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Eiken Chemical Co's enterprise value is 円72,039 Mil.
Eiken Chemical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円7,240 Mil. Therefore, Eiken Chemical Co's EV-to-EBITDA for today is 9.95.
The historical rank and industry rank for Eiken Chemical Co's EV-to-EBITDA or its related term are showing as below:
TSE:4549'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.62 Med: 12.39 Max: 25.57
Current: 9.94
During the past 13 years, the highest EV-to-EBITDA of Eiken Chemical Co was 25.57. The lowest was 4.62. And the median was 12.39.
TSE:4549's EV-to-EBITDA is ranked better than 65.39% of 523
companies
in the Medical Devices & Instruments industry
Industry Median: 14.62
vs TSE:4549: 9.94
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Eiken Chemical Co (TSE:4549) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Eiken Chemical Co's PE Ratio (TTM) for today is calculated as:
Eiken Chemical Co's share price for today is 円2307.00.
Eiken Chemical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円107.530.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Eiken Chemical Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4549 vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Eiken Chemical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eiken Chemical Co EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Eiken Chemical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Eiken Chemical Co's EV-to-EBITDA falls into.
Eiken Chemical Co's current Enterprise Value is 円72,039 Mil.
Eiken Chemical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円7,240 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eiken Chemical Co (TSE:4549) has a EV-to-EBITDA of 9.95 as of Aug. 28, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Eiken Chemical Co. This is 20% below median its historical median of 12.39. Over the past decade, Eiken Chemical Co's EV-to-EBITDA has ranged from 4.62 to 25.57. According to the industry distribution chart, Eiken Chemical Co ranks #181 out of 523 companies in the Medical Devices & Instruments industry, placing it in the top 34.6%.
Is Eiken Chemical Co's EV-to-EBITDA too high?
Eiken Chemical Co's current EV-to-EBITDA of 9.95 is 20% below median its 10-year median of 12.39. Over the past 10 years, this metric has ranged from a low of 4.62 to a high of 25.57. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.62. Eiken Chemical Co's value of 9.95 is 31.9% below this industry median. Based on the distribution chart, Eiken Chemical Co ranks #181 out of 523 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Eiken Chemical Co has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eiken Chemical Co's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Eiken Chemical Co ranks #181 out of 523 companies for EV-to-EBITDA. This puts Eiken Chemical Co in the upper half of its industry. The industry median EV-to-EBITDA is 14.62. Eiken Chemical Co's value of 9.95 is 31.9% below this benchmark. Historically, Eiken Chemical Co's own EV-to-EBITDA has ranged from 4.62 to 25.57 over the past decade. While the company's 10-year median is 12.39 vs. the industry median of 14.62, Eiken Chemical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.62, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eiken Chemical Co's current EV-to-EBITDA of 9.95 is 31.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Eiken Chemical Co. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eiken Chemical Co's current EV-to-EBITDA is 9.95, which is 20% below median its own 10-year median of 12.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eiken Chemical Co stock overvalued right now?
Based on GuruFocus' analysis, Eiken Chemical Co (TSE:4549) is currently considered Fairly Valued. The stock's GF Value™ is 円2,494.71, compared to a current price of 円2,307.00 — trading 7.5% below its estimated fair value. The current EV-to-EBITDA is 9.95, which is 20% below median its 10-year median of 12.39 and 31.9% below the Medical Devices & Instruments industry median of 14.62. Eiken Chemical Co's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Eiken Chemical Co (TSE:4549), the current EV-to-EBITDA is 9.95 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eiken Chemical Co (TSE:4549) Overvalued in 2026?
Based on GuruFocus' analysis, Eiken Chemical Co stock appears to be undervalued.
The current stock price of 円2,307.00 is trading 7.5% below its estimated GF Value™ of 円2,494.71.
GuruFocus considers Eiken Chemical Co to be Fairly Valued.
Key valuation signals for TSE:4549:
EV-to-EBITDA: 9.95 (20% below median its 10-year median of 12.39)
GF Value™: 円2,494.71 vs. price of 円2,307.00 (7.5% below fair value)
Industry Position: 31.9% below the Medical Devices & Instruments median (#181 of 523)
No single metric tells the full story. See the TSE:4549 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eiken Chemical Co Ltd is a Japan-based company. It manufactures and sells clinical diagnostics and equipment. The company is engaged in processing, manufacture, purchase and sale of test agents, property and casualty insurance agency business. It as a general manufacturer of clinical diagnostics offers a wide range of in vitro diagnostic aids for all fields of medicine. Its major products include the Fecal immunochemical test, Molecular Genetics (LAMP), Microbiology, among many others.
79GF Score
Get the complete analysis for TSE:4549
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4549 has been successfully added to your 
